Creative Biogene Expands Antibody Purification Platform to Support Biotechnology Innovation

Creative Biogene has expanded its antibody purification platform to provide a streamlined purification workflow for producing high-yield, high-purity antibodies from scalable and customizable protocols. The platform refines antibody purification strategies from various expression sources and is available for companies and research institutions to aid in the growing need for consistent and efficient antibody preparations.

The platform features a robust purification workflow incorporating capture, intermediate, and polishing steps. Protein A/G/L resins are utilized for Fc-binding antibodies, while ion exchange chromatography is available for charge-based purification and size exclusion chromatography for removing aggregates, ensuring final antibody purity of greater than 95%. The platform also features orthogonal and complementary processes, including hydrophobic interaction chromatography, multimodal, and buffer exchange.

Complementary quality control services include SDS-PAGE, SEC-HPLC, and endotoxin testing, with results delivered in a Certificate of Analysis report. A comprehensive range of equipment supports the platform, with chromatography columns that are compact and easy to operate. Process chromatography systems are available at laboratory and pilot scales, allowing customizable system design.

Buffer dilution and conditioning systems enable precise formulation while reducing resource use. Filtration systems, including tangential flow, depth filtration, and single-use options, ensure fast turnaround between runs. These assets provide a complete and flexible solution for antibody purification that addresses critical needs in biotechnology research and development.

The platform is designed for various biotechnology applications, with antibody materials suitable for antibody candidate development programs, assay optimization, production of kit components, and as research reagents. According to Marcia Brady's Chief Expert, evaluation of the platform indicated that its main value comes from well-balanced throughput and reproducibility. The platform has been optimized to provide consistent results across various scales and antibody targets, allowing researchers to streamline their work.

Creative Biogene plans to continue improving the system with more automation features and increased scalability. Through future integration and continued refinement of purification protocols and scalable design, the company will provide comprehensive solutions for current and future research needs. For additional details, visit https://www.creative-biogene.com.